Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

The future of GLP-1 drugs is looking bigger than anyone predicted. As governments consider broader adoption and competitors scramble to keep up, Novo Nordisk is well-positioned to lead this ...

I see that Novo Nordisk is cheaper than its main competitor ... clear signs of a turnaround in investor sentiment. Don't get me wrong. In the long term, I believe the company is a solid buy.

Novo Nordisk A/S’s blockbuster drug Wegovy was ... 17.5% reduction among people who got a standard dose — but was less than either the highest dose of Eli Lilly & Co.’s Zepbound or the ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in ... "As the base gets bigger and bigger, the relative growth becomes smaller.

CagriSema could still be a commercial success, though, and amycretin's recent results highlight the fact that Novo Nordisk's weight loss pipeline is deep. And regarding the slower-than-expected ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab ... Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy, but investors ...